Yumanity Therapeutics to Present at the 2021 B. Riley Securities’ Neuroscience Conference

The Company\xe2\x80\x99s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\xe2\x80\x99s disease.